FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer

The U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib in May 2020 for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)‐associated metastatic castrate‐resistant prostate cancer (mCRPC) who have been treated with androgen receptor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Anscher, Mitchell S., Chang, Elaine, Gao, Xin, Gong, Yutao, Weinstock, Chana, Bloomquist, Erik, Adeniyi, Oluseyi, Charlab, Rosane, Zimmerman, Sarah, Serlemitsos‐Day, Maritsa, Ning, Yang Min, Mayrosh, Ruth, Fuller, Barbara, Trentacosti, Ann Marie, Gallagher, Pamela, Bijwaard, Karen, Philip, Reena, Ghosh, Soma, Fahnbulleh, Frances, Diggs, Felicia, Arora, Shaily, Goldberg, Kirsten B., Tang, Shenghui, Amiri‐Kordestani, Laleh, Pazdur, Richard, Ibrahim, Amna, Beaver, Julia A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Regulatory Issues: FDA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873319/
https://ncbi.nlm.nih.gov/pubmed/33145877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13585
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados